@article{MTMT:34833014,
	title = {A Belügyminisztérium egészségügyi szakmai irányelve az epilepsziás rohamok és epilepszia felismeréséről, kezeléséről és az epilepsziás betegek gondozásáról},
	url = {https://m2.mtmt.hu/api/publication/34833014},
	author = {Óváry, Csaba and Bereczki, Csaba and Gődény, Mária and Battyáni, István and Kovács, Péter and Fogarasi, András and Janszky, József and Juhos, Vera and Rosdy, Beáta and Hollódy, Katalin and Bessenyei, Mónika and Barsi, Péter and Martos, János and Békés, Judit and Borbély, Katalin},
	journal-iso = {EGÉSZSÉGÜGYI KÖZLÖNY},
	journal = {EGÉSZSÉGÜGYI KÖZLÖNY},
	volume = {74},
	unique-id = {34833014},
	issn = {2063-1146},
	year = {2024},
	pages = {1256-1310},
	orcid-numbers = {Gődény, Mária/0000-0003-0020-3476; Kovács, Péter/0009-0003-6352-2113; Borbély, Katalin/0000-0002-1675-4128}
}

@article{MTMT:34832954,
	title = {A Belügyminisztérium egészségügyi szakmai irányelve a pszichoterápiás ellátásról},
	url = {https://m2.mtmt.hu/api/publication/34832954},
	author = {Kovács, Péter and Németh, Attila and Gonda, Xénia and Csigó, Katalin and Purebl, György and Kiss, Dániel Balázs and Ozvald, Gabriella},
	journal-iso = {EGÉSZSÉGÜGYI KÖZLÖNY},
	journal = {EGÉSZSÉGÜGYI KÖZLÖNY},
	volume = {74},
	unique-id = {34832954},
	issn = {2063-1146},
	year = {2024},
	pages = {909-1043},
	orcid-numbers = {Kovács, Péter/0009-0003-6352-2113; Gonda, Xénia/0000-0001-9015-4203; Purebl, György/0000-0002-9750-2001}
}

@article{MTMT:34827151,
	title = {DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.},
	url = {https://m2.mtmt.hu/api/publication/34827151},
	author = {Suba, Zsuzsanna},
	doi = {10.3390/cancers16081573},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {16},
	unique-id = {34827151},
	abstract = {In tumors, somatic mutagenesis presumably drives the DNA damage response (DDR) via altered regulatory pathways, increasing genomic instability and proliferative activity. These considerations led to the standard therapeutic strategy against cancer: the disruption of mutation-activated DNA repair pathways of tumors.Justifying that cancer cells are not enemies to be killed, but rather that they are ill human cells which have the remnants of physiologic regulatory pathways.1. Genomic instability and cancer development may be originated from a flaw in estrogen signaling rather than excessive estrogen signaling; 2. Healthy cells with genomic instability exhibit somatic mutations, helping DNA restitution; 3. Somatic mutations in tumor cells aim for the restoration of DNA damage, rather than further genomic derangement; 4. In tumors, estrogen signaling drives the pathways of DNA stabilization, leading to apoptotic death; 5. In peritumoral cellular infiltration, the genomic damage of the tumor induces inflammatory cytokine secretion and increased estrogen synthesis. In the inflammatory cells, an increased growth factor receptor (GFR) signaling confers the unliganded activation of estrogen receptors (ERs); 6. In breast cancer cells responsive to genotoxic therapy, constitutive mutations help the upregulation of estrogen signaling and consequential apoptosis. In breast tumors non-responsive to genotoxic therapy, the possibilities for ER activation via either liganded or unliganded pathways are exhausted, leading to farther genomic instability and unrestrained proliferation.Understanding the real character and behavior of human tumors at the molecular level suggests that we should learn the genome repairing methods of tumors and follow them by supportive therapy, rather than provoking additional genomic damages.},
	keywords = {MUTATION; ESTROGEN; DNA Repair; cancer therapy; DNA Damage; Estrogen receptor; growth factor receptor; endocrine disruptor; DNA damage response; Anti-estrogen},
	year = {2024},
	eissn = {2072-6694}
}

@article{MTMT:34827138,
	title = {(Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand.},
	url = {https://m2.mtmt.hu/api/publication/34827138},
	author = {Ludwig, Gerd and Randelovic, Ivan and Dimić, Dušan and Komazec, Teodora and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Rüffer, Tobias and Kaluđerović, Goran N},
	doi = {10.3390/biom14040420},
	journal-iso = {BIOMOLECULES},
	journal = {BIOMOLECULES},
	volume = {14},
	unique-id = {34827138},
	issn = {2218-273X},
	abstract = {The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κP,κS-bonded Ph2PCH2CH2SPh ligand ([Ir(η5-C5Me5)Cl(Ph2P(CH2)2SPh-κP,κS)]PF6, (1)] was synthesized and characterized. Multinuclear (1H, 13C and 31P) NMR spectroscopy was employed for the determination of the structure. Moreover, SC-XRD confirmed the proposed structure belongs to the "piano stool" type. The Hirshfeld surface analysis outlined the most important intermolecular interactions in the structure. The crystallographic structure was optimized at the B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir) level of theory. The applicability of this level was verified through a comparison of experimental and theoretical bond lengths and angles, and 1H and 13C NMR chemical shifts. The Natural Bond Orbital theory was used to identify and quantify the intramolecular stabilization interactions, especially those between donor atoms and Ir(III) ions. Complex 1 was tested on antitumor activity against five human tumor cell lines: MCF-7 breast adenocarcinoma, SW480 colon adenocarcinoma, 518A2 melanoma, 8505C human thyroid carcinoma and A253 submandibular carcinoma. Complex 1 showed superior antitumor activity against cisplatin-resistant MCF-7, SW480 and 8505C cell lines. The mechanism of tumoricidal action on 8505C cells indicates the involvement of caspase-induced apoptosis, accompanied by a considerable reduction in ROS/RNS and proliferation potential of treated cells.},
	keywords = {APOPTOSIS; In Vitro; IRIDIUM(III); Pentamethylcyclopentadienyl ligand; anaplastic thyroid tumor 8505C},
	year = {2024},
	eissn = {2218-273X},
	orcid-numbers = {Randelovic, Ivan/0000-0003-0161-0022}
}

@article{MTMT:34827132,
	title = {First-line avelumab plus chemotherapy in patients with advanced solid tumors. results from the phase 1b/2 JAVELIN Chemotherapy Medley study.},
	url = {https://m2.mtmt.hu/api/publication/34827132},
	author = {Wheatley, Duncan A and Berardi, Rossana and Climent Duran, Miguel A and Tomiak, Anna and Greystoke, Alastair P and Joshua, Anthony M and Arkenau, Hendrik-Tobias and Géczi, Lajos and Garcia-Corbacho, Javier and Paz-Ares, Luis G and Hussain, Syed A and Petruželka, Lubos and Delmonte, Angelo and Chappey, Colombe and Masters, Joanna C and Michelon, Elisabete and Murphy, Danielle A and Mwewa, Sandrine and Cesari, Rossano and Doger de Speville, Bernard},
	doi = {10.1158/2767-9764.CRC-23-0459},
	journal = {Cancer Research Communications},
	volume = {Apr 26},
	unique-id = {34827132},
	abstract = {Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase 1b/2 JAVELIN Chemotherapy Medley trial evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or nonsmall cell lung cancer (NSCLC).Avelumab 800 mg or 1200 mg was administered continuously every 3 weeks (Q3W) with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase 1b) and confirmed objective response (phase 1b/2).In phase 1b, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n=13 and n=6, respectively) or 1200 mg (n=6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 mg or 1200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase 2, 35 additional patients with urothelial carcinoma received avelumab 1200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 mg or 1200 mg + chemotherapy, respectively, across phase 1b/2, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC.Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers.gov identifier, NCT03317496.},
	year = {2024},
	eissn = {2767-9764},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}

@article{MTMT:34805400,
	title = {Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.},
	url = {https://m2.mtmt.hu/api/publication/34805400},
	author = {Wéber, András and Vignat, Jerome and Shah, Richa and Morgan, Eileen and Laversanne, Mathieu and Nagy, Péter and Kenessey, István and Znaor, Ariana},
	doi = {10.1007/s00345-024-04949-8},
	journal-iso = {WORLD J UROL},
	journal = {WORLD JOURNAL OF UROLOGY},
	volume = {42},
	unique-id = {34805400},
	issn = {0724-4983},
	abstract = {In 2020, bladder cancer (BC) was the seventh most prevalent cancer in the world, with 5-year prevalence of more than 1.7 million cases. Due to the main risk factors-smoking and chemical exposures-associated with BC, it is considered a largely preventable and avoidable cancer. An overview of BC mortality can allow an insight not only into the prevalence of global risk factors, but also into the varying efficiency of healthcare systems worldwide. For this purpose, this study analyzes the national mortality estimates for 2020 and projected future trends up to 2040.Age-standardized mortality rates per 100,000 person-years of BC for 185 countries by sex were obtained from the GLOBOCAN 2020 database, operated by the International Agency for Research on Cancer (IARC). Mortality rates were stratified according to sex and Human Development Index (HDI). BC deaths were projected up to 2040 on the basis of demographic changes, alongside different scenarios of annually increasing, stable or decreasing mortality rates from the baseline year of 2020.In 2020, nearly three times more men died from BC than women, with more than 210,000 deaths in both sexes combined, worldwide. Regardless of gender, more than half of the total BC deaths were from countries with a very high HDI. According to our projections, while the number of deaths for men can only increase up to 54% (from 159 to around 163-245 thousand), for women it is projected to increase two- to three-fold (from 50 to around 119-176 thousand) by 2040. The burden of BC mortality in countries with a very high HDI versus high HDI appears to converge by 2040 for both sexes.Opposite mortality trends by gender highlight the urgent need for immediate interventions to expand anti-tobacco strategies, especially for women. The implementation of more strict occupational health and safety regulations could also prevent exposures associated with BC. Improving the ability to detect BC earlier and access to treatment can have a significant positive impact on reducing mortality rates, minimizing economic costs, and enhancing the quality of life for patients.},
	keywords = {MORTALITY; bladder cancer; PROJECTION},
	year = {2024},
	eissn = {1433-8726},
	orcid-numbers = {Wéber, András/0000-0003-1605-8226; Nagy, Péter/0000-0003-3393-235X; Kenessey, István/0000-0002-6963-8489}
}

@article{MTMT:34805365,
	title = {Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy. the ARON-2 study.},
	url = {https://m2.mtmt.hu/api/publication/34805365},
	author = {Massari, Francesco and Santoni, Matteo and Takeshita, Hideki and Okada, Yohei and Tapia, Jose Carlos and Basso, Umberto and Maruzzo, Marco and Scagliarini, Sarah and Büttner, Thomas and Fornarini, Giuseppe and Myint, Zin W and Galli, Luca and Souza, Vinicius Carrera and Pichler, Renate and De Giorgi, Ugo and Gandur, Nathalia and Lam, Elaine T and Gilbert, Danielle and Popovic, Lazar and Grande, Enrique and Mammone, Giulia and Berardi, Rossana and Crabb, Simon J and Kemp, Robert and Molina-Cerrillo, Javier and Freitas, Marcelo and Luz, Murilo and Iacovelli, Roberto and Calabrò, Fabio and Tural, Deniz and Atzori, Francesco and Küronya, Zsófia and Chiari, Rita and Campos, Saul and Caffo, Orazio and Fay, André P and Kucharz, Jakub and Zucali, Paolo Andrea and Rinck, José Augusto and Zeppellini, Annalisa and Bastos, Diogo Assed and Aurilio, Gaetano and Mota, Augusto and Trindade, Karine and Ortega, Cinzia and Sade, Juan Pablo and Rizzo, Mimma and Fiala, Ondřej and Vau, Nuno and Giannatempo, Patrizia and Barillas, Allan and Monteiro, Fernando Sabino M and Dauster, Breno and Mennitto, Alessia and Nogueira, Lucas and de Carvalho Fernandes, Roni and Seront, Emmanuel and Aceituno, Luís Garcia and Grillone, Francesco and Cutuli, Hernan Javier and Fernandez, Mauricio and Bassanelli, Maria and Kopp, Ray Manneh and Roviello, Giandomenico and Abahssain, Halima and Procopio, Giuseppe and Milella, Michele and Kopecky, Jindrich and Martignetti, Angelo and Messina, Carlo and Caitano, Manuel and Inman, Eva and Kanesvaran, Ravindran and Herchhorn, Daniel and Santini, Daniele and Bamias, Aristotelis and Bisonni, Renato and Mosca, Alessandra and Morelli, Franco and Maluf, Fernando and Soares, Andrey and Nunes, Fernando and Pinto, Alvaro and Zgura, Anca and Incorvaia, Lorena and Ansari, Jawaher and Zabalza, Ignacio Ortego and Landmesser, Johannes and Rizzo, Alessandro and Mollica, Veronica and Marchetti, Andrea and Rosellini, Matteo and Sorgentoni, Giulia and Battelli, Nicola and Buti, Sebastiano and Porta, Camillo and Bellmunt, Joaquim},
	doi = {10.1007/s00262-024-03682-w},
	journal-iso = {CANCER IMMUNOL IMMUN},
	journal = {CANCER IMMUNOLOGY IMMUNOTHERAPY},
	volume = {73},
	unique-id = {34805365},
	issn = {1432-0851},
	abstract = {Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy.Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors.In total, 836 patients were included: 544 patients (65%) received pembrolizumab after progression to first-line platinum-based chemotherapy in the metastatic setting (cohort A) and 292 (35%) after recurring within < 12 months since the completion of adjuvant or neoadjuvant chemotherapy (cohort B). The median follow-up time was 15.3 months. The median OS and the ORR were 10.5 months and 31% in the overall study population, 9.1 months and 29% in cohort A and 14.6 months and 37% in cohort B. At multivariate analysis, ECOG-PS ≥ 2, bone metastases, liver metastases and pembrolizumab setting (cohort A vs B) proved to be significantly associated with worst OS and PFS. Stratified by the presence of 0, 1-2 or 3-4 prognostic factors, the median OS was 29.4, 12.5 and 4.1 months (p < 0.001), while the median PFS was 12.2, 6.4 and 2.8 months, respectively (p < 0.001).Our study confirms that pembrolizumab is effective in the advanced UC real-world context, showing outcome differences between patients recurred or progressed after platinum-based chemotherapy.},
	keywords = {SURVIVAL; Urothelial cancer; TUMOR RESPONSE; pembrolizumab; Real-world data; ARON-2 study},
	year = {2024},
	eissn = {0340-7004},
	pages = {106},
	orcid-numbers = {Küronya, Zsófia/0000-0001-8500-5924}
}

@misc{MTMT:34795787,
	title = {Célzott sugárkezelés és sugársebészet},
	url = {https://m2.mtmt.hu/api/publication/34795787},
	author = {Jánváry, Zsolt Levente},
	unique-id = {34795787},
	year = {2024},
	orcid-numbers = {Jánváry, Zsolt Levente/0000-0002-4583-4901}
}

@misc{MTMT:34795710,
	title = {Urológiai daganatok gyógyszeres kezelése},
	url = {https://m2.mtmt.hu/api/publication/34795710},
	author = {Bíró, Krisztina},
	unique-id = {34795710},
	year = {2024},
	orcid-numbers = {Bíró, Krisztina/0000-0002-2070-0608}
}

@misc{MTMT:34795682,
	title = {Urológiai daganatok sugárkezelése},
	url = {https://m2.mtmt.hu/api/publication/34795682},
	author = {Gesztesi, László},
	unique-id = {34795682},
	year = {2024}
}